Aarti Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2021
May 15, 2021 at 11:39 am EDT
Share
Aarti Drugs Limited announced earnings results for the full year ended March 31, 2021. For the full year, the company announced total revenue was INR 21,593 million compared to INR 18,075.7 million a year ago. Net income was INR 2,804.1 million compared to INR 1,414 million a year ago. Basic earnings per share from continuing operations was INR 30.09 compared to INR 15.14 a year ago.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
